ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study

Lu, Shun*; Zhou, Jianying*; Jian, Hong; Wu, Lin; Cheng, Ying; Fan, Yun; Fang, Jian; Chen, Gongyan; Zhang, Zhihong; Lv, Dongqing; Jiang, Liyan; Wu, Rong; Jin, Xiangming; Zhang, Xiaodong; Zhang, Junhong; Xie, Conghua; Sun, Gengyun; Huang, Dongning; Cui, Jiuwei; Guo, Renhua; Han, Zhigang; Chen, Zhendong; Liang, Jin; Zhuang, Wu; Hu, Xingsheng; Zang, Aimin; Zhang, Yi; Cang, Shundong; Lan, Yuanbo; Chen, Xi; Liu, Laiyu; Li, Xingya; Chen, Jun; Ma, Rui; Guo, Yanzhen; Sun, Ping安徽医科大学; 吉林大学; 南方医科大学; 青岛大学; 上海交通大学; 哈尔滨医科大学; 四川大学; 浙江大学; 郑州大学; 武汉大学; 中国医科大学; 中国医学科学院; 中国科学院研究生院; 中国医学科学院北京协和医院; 1
Lancet Respiratory Medicine2023-10DOI: 10.1016/S2213-2600(23)00183-2
6被引21阅读
引用收藏
分享

摘要

Background Befotertinib (D-0316) is a novel, selective oral third-generation epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor. This phase 3 trial compared the efficacy and safety of befotertinib with icotinib as a first-line treatment for patients with EGFR mutation-positive locally advanced or metastatic non-small-cell lung cancer (NSCLC).Methods This study was a multicentre, open-label, randomised, controlled phase 3 study at 39 hospitals in China. Eligible patients were 18 years of age or older, had histologically confirmed locally advanced or metastatic stage IIIB, IIIC, or IV unresectable NSCLC, and had confirmed exon 19 deletions or exon 21 Leu858Arg mutation. Patients were randomly assigned (1:1) via an interactive web response system to receive either oral befotertinib (75-100 mg once daily) or oral icotinib (125 mg three times per day) in 21-day cycles until disease progression or withdrawal criteria were met. Randomisation was stratified by type of EGFR mutation, CNS metastasis status, and gender, and participants, investigators, and data analysts were not masked to treatment allocation. The primary endpoint was independent review committee (IRC)-assessed progression-free survival in the full analysis set, which comprised all randomly assigned patients. All patients who received at least one dose of the study drug were included in safety analyses. This study was registered with ClinicalTrials.gov, NCT04206072, and the overall survival follow-up is still in progress. Findings Between Dec 24, 2019, and Dec 18, 2020, 568 patients were screened, of whom 362 were randomly assigned to the befotertinib (n=182) or icotinib (n=180) group; all 362 patients were included in the full analysis set. Median follow-up was 20<middle dot>7 months (IQR 10<middle dot>2-23<middle dot>5) in the befotertinib group and 19<middle dot>4 months (10<middle dot>3-23<middle dot>5) in the icotinib group. Median IRC-assessed progression-free survival was 22<middle dot>1 months (95% CI 17<middle dot>9-not estimable) in the befotertinib group and 13<middle dot>8 months (12<middle dot>4-15<middle dot>2) in the icotinib group (hazard ratio 0<middle dot>49 [95% CI 0<middle dot>36-0<middle dot>68], p<0<middle dot>0001). Grade 3 or higher treatment-related adverse events occurred in 55 (30%) of 182 patients in the befotertinib group and in 14 (8%) of 180 patients in the icotinib group. Treatment-related serious adverse events were reported in 37 (20%) patients in the befotertinib group and in five (3%) patients in the icotinib group. Two (1%) patients in the befotertinib group and one (1%) patient in the icotinib group died due to treatment-related adverse events.Interpretation Befotertinib demonstrated superior efficacy compared with icotinib in first-line treatment for patients with EGFR mutation-positive NSCLC. Although serious adverse events were more common in the befotertinib than the icotinib arm, the safety profile of befotertinib was manageable overall.

学科与关键词

关键词
FACTOR RECEPTOR MUTATIONSQUALITY-OF-LIFEGEFITINIBOSIMERTINIBERLOTINIB
相关
加载中…
  • Efficacy and Safety of Befotertinib (D-0316) in Patients With EGFR T790M-Mutated NSCLC That Had Progressed After Prior EGFR Tyrosine Kinase Inhibitor Therapy: A Phase 2, Multicenter, Single-Arm, Open-Label Study
    Lu, Shun; Zhang, Yiping; Zhang, Guojun; Zhou, Jianying; Cang, Shundong; Cheng, Ying; Wu, Gang; Cao, Peiguo; Lv, Dongqing; Jian, Hong; Chen, Chengshui; Jin, Xiangming; Tian, Panwen; Wang, Kai; Jiang, Guanming; Chen, Gongyan; Chen, Qun; Zhao, Hui; Ding, Cuimin; Guo, Renhua; Sun, Guoping; Wang, Bin; Jiang, Liyan; Liu, Zhe; Fang, Jian; Yang, Junquan; Zhuang, Wu; Liu, Yunpeng; Zhang, Jian; Pan, Yueyin; Chen, Jun; Yu, Qitao; Zhao, Min; Cui, Jiuwei; Li, Dianming; Yi, Tienan; Yu, Zhuang; Yang, YanJournal of Thoracic Oncology, 2022, 17(10): 1192-1204.被引 7
  • Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer: A multicentre, open-label, randomized phase III study
    Lu, S.; Zhou, J.; Jian, H.; Wu, L.; Cheng, Y.; Fan, Y.; Fang, J.; Chen, G.; Zhang, Z.; Lv, D.; Jiang, L.; Wu, R.; Jin, X.; Zhang, X.; Zhang, J.; Sun, G.; Huang, D.; Cui, J.; Guo, R.; Ding, L.ESMO Asia Congress, Singapore, SINGAPORE, 2022-12-02 To 2022-12-04.
  • A Phase 2 Study of Befotertinib in Patients with EGFR T790M Mutated NSCLC after Prior EGFR TKIs
    Lu, S.; Zhang, Y.; Zhang, G.; Zhou, J.; Cang, S.; Cheng, Y.; Wu, G.; Cao, P.; Lv, D.; Jian, H.; Chen, C.; Jin, X.; Tian, P.; Wang, K.; Jiang, G.; Chen, G.; Chen, Q.; Zhao, H.; Ding, C.; Guo, R.; Sun, G.; Wang, B.; Jiang, L.; Liu, Z.; Fang, J.; Yang, J.; Zhuang, W.; Liu, Y.; Zhang, J.; Pan, Y.; Chen, J.; Yu, Q.; Zhao, M.; Cui, J.; Li, D.; Yi, T.; Yu, Z.; Yang, Y.; Zhang, Y.; Zhi, X.; Huang, Y.; Wu, R.; Chen, L.; Zang, A.; Cao, L.; Li, Q.; Li, X.; Song, Y.; Wang, D.; Zhang, S.
查看全部 →

发表信息

论文状态
公开发表
期刊
Lancet Respiratory Medicine
发表日期
2023-10
卷期
第 11 卷, 第 10 期
页码
905-915
DOI
10.1016/S2213-2600(23)00183-2
语言
ENGLISH
成果收录
SCIE
资助标注
Betta Pharmaceuticals (China)

作者

  • L

    Lu, Shun (通讯) (第一作者)

    shanghai jiao tong univ

  • Z

    Zhou, Jianying (通讯)

    1 · zhejiang univ

查看全部 44 位作者收起作者
  • J

    Jian, Hong

    shanghai jiao tong univ

  • W

    Wu, Lin

    2 · hunan canc hosp

  • C

    Cheng, Ying

  • F

    Fan, Yun

    2 · univ chinese acad sci · zhejiang canc hosp

  • F

    Fang, Jian

  • C

    Chen, Gongyan

    harbin med univ

  • Z

    Zhang, Zhihong

  • L

    Lv, Dongqing

  • J

    Jiang, Liyan

  • W

    Wu, Rong

    2 · china med univ · liaoning canc hosp & inst

  • J

    Jin, Xiangming

    ningxia med univ

  • Z

    Zhang, Xiaodong

    nantong tumor hosp

  • Z

    Zhang, Junhong

    wuhan univ

  • X

    Xie, Conghua

    wuhan univ

  • S

    Sun, Gengyun

    1 · anhui med univ

  • H

    Huang, Dongning

    liuzhou workers hosp

  • C

    Cui, Jiuwei

    jilin univ

  • G

    Guo, Renhua

    1 · nanjing med univ

  • H

    Han, Zhigang

    xinjiang med univ

  • C

    Chen, Zhendong

    2 · anhui med univ

  • L

    Liang, Jin

    1 · kunming med univ

  • Z

    Zhuang, Wu

    fujian canc hosp

  • H

    Hu, Xingsheng

    chinese acad med sci · peking union med coll

  • Z

    Zang, Aimin

    hebei univ

  • Z

    Zhang, Yi

    capital med univ

  • C

    Cang, Shundong

    henan prov peoples hosp

  • L

    Lan, Yuanbo

    2

  • C

    Chen, Xi

  • L

    Liu, Laiyu

    southern med univ

  • L

    Li, Xingya

    1 · zhengzhou univ

  • C

    Chen, Jun

    tianjin med univ

  • M

    Ma, Rui

  • G

    Guo, Yanzhen

    1 · henan univ

  • S

    Sun, Ping

    2 · affiliated yantai yuhuangding hosp · qindao univ

  • T

    Tian, Panwen

    sichuan univ

  • P

    Pan, Yueyin

    anhui prov hosp

  • L

    Liu, Zhe

    beijing chest hosp · capital med univ

  • C

    Cao, Peiguo

  • D

    Ding, Lieming

  • W

    Wang, Yang

  • Y

    Yuan, Xiaobin

  • W

    Wu, Pengxiang

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417